Lamont Weide, MD, PhD, FACE
Basic profileLamont Weide is an Endocrinology/Metabolic physician affiliated with University of Missouri–Kansas City. OpenAlex indexes 48 publications with 1,468 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment$15
- Lilly USA, LLCProgram year20234 payments$70
- ANI Pharmaceuticals, Inc.Program year20231 payment$32
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
41.9%Statin14.8%Atorvastatin Calcium74%Rosuvastatin Calcium17%Pravastatin Sodium7%Lovastatin2%Part D<11 patientsCalcium channel blocker5.6%Amlodipine Besylate94%Nifedipine Er6%Part D<11 patients+ 12 more classes in this area
Metabolism & gastrointestinal
39.9%GLP-1 receptor agonist11.1%Trulicity47%Ozempic40%Victoza 3-Pak6%Rybelsus4%Victoza 2-Pak3%Part D<11 patientsInsulin Analog11.1%Lantus Solostar36%Novolog Flexpen21%Humalog Kwikpen U-10011%Novolog7%Insulin Lispro Kwikpen U-1007%Tresiba Flextouch U-1006%Basaglar Kwikpen U-1006%Tresiba Flextouch U-2003%Humalog3%Part D<11 patients+ 8 more classes in this area
Hormonal (systemic)
14.7%l-Thyroxine12.9%Levothyroxine Sodium87%Synthroid13%Part D≥112 patientsThyroid Hormone Synthesis Inhibitor1.5%Methimazole100%Part D≥14 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Synchronous muscle and bone metastases in thyroid cancer
Journal of Clinical and Translational Endocrinology Case Reports
2025 - SAT-584 Skeletal Muscle and Bone Metastases in Papillary Thyroid Microcarcinoma
Journal of the Endocrine Society
2024 - A Case-Based Comparison of the American Thyroid Association and Thyroid Imaging Reporting & Data System Guidelines.
PubMed
2022
Similar KOLs
Other experts from the same institution or the same specialty.
John Spertus, MD
University of Missouri–Kansas City
Barry Rutherford, MD
University of Missouri–Kansas City
Gary Lofland, MD
University of Missouri–Kansas City
Jessica Hellings, MD
University of Missouri–Kansas City
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”